LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia

Janani Ravikrishnan(The Ohio State University), Deepa Sampath(The University of Texas MD Anderson Cancer Center), Xiaokui Mo(The Ohio State University), Gerard Lozanski(The Ohio State University), Nitin Jain(Parul University), John R. Sanchez(The University of Texas MD Anderson Cancer Center), Rosa Lapalombella(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Stephen P. Anthony, Fenlai Tan(Betta Pharmaceuticals (China)), Mary C. Collins(Dana-Farber Cancer Institute), Elizabeth J. Perry(The Ohio State University), Suresh Satpati(The University of Texas MD Anderson Cancer Center), Seema A. Bhat(The Ohio State University), Matthew S. Davids(Dana-Farber Cancer Institute), Arletta Lozanski(The Ohio State University), Shrilekha Misra(The Ohio State University), Yue Shen(University of Illinois Urbana-Champaign), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Andrew D. Mitchell(University College London), Charmelle D. Williams(The University of Texas MD Anderson Cancer Center), Yi Chen(Sichuan University of Arts and Science), Yu Chen, Chaomei Liu(The University of Texas MD Anderson Cancer Center), Daisy Y. Diaz-Rohena(The University of Texas MD Anderson Cancer Center), Jennifer A. Woyach(The Ohio State University), Tierney Kaufman(The Ohio State University), KerryA Rogers(The Ohio State University), William G. Wierda(The University of Texas MD Anderson Cancer Center), John C. Byrd(University of Cincinnati), Tzung-Huei Lai(The Ohio State University), Elizabeth M. Muhowski(The Ohio State University)
Haematologica
August 8, 2024
Cited by 12


Related Papers